Abstract
Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 22-24 |
| Numero di pagine | 3 |
| Rivista | THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE |
| Volume | 24 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2011 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- Adult
- Antifungal Agents
- Chemoprevention
- Child
- Echinocandins
- Humans
- Infant
- Intensive Care Units
- Mycoses
- Newborn
- Pediatric
- Risk Factors
Fingerprint
Entra nei temi di ricerca di 'Fungal infections in pediatric intensive care units'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver